“I think this represents an entirely new way of treating bladder cancer,” says William C. Huang, MD.
In this interview, recorded at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana, William C. Huang, MD, discusses the OPTIMA II and ENIVISION trials evaluating UGN-102 in non–muscle-invasive bladder cancer. Huang is professor and vice chair for clinical affairs in the Department of Urology at NYU Grossman School of Medicine in New York, New York.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.